证券日报网讯达嘉维康（301126）8月19日在互动平台回答投资者提问时表示，截至2025年8月8日，公 司股东人数为19805户。 ...

从资金流向上来看，当日医药商业板块主力资金净流入4.72亿元，游资资金净流出2.9亿元，散户资金净 流出1.82亿元。医药商业板块个股资金流向见下表： 证券之星消息，8月19日医药商业板块较上一交易日上涨0.63%，塞力医疗领涨。当日上证指数报收于 3727.29，下跌0.02%。深证成指报收于11821.63，下跌0.12%。医药商业板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 603716 | 塞力医疗 | 31.40 | 5.12% | 61.67万 | | 19.77亿 | | 301408 | 华人健康 | 15.41 | 3.98% | 24.10万 | | 3.67亿 | | 301126 | 达嘉维康 | 13.24 | 3.36% | 19.13万 | | 2.54亿 | | 600538 | 国发股份 | 6.28 | 2.95% | 19.80万 | | 1.22亿 | | 603122 | 合富中国 | 7.25 | 2.55% | ...

Group 1 - The number of shareholders for Dajia Weikang as of August 10 is 19,805, a decrease of 1,648 from the previous period (July 31), representing a decline of 7.68% [2] - The latest stock price for Dajia Weikang is 12.87 yuan, an increase of 0.47%, with a cumulative increase of 2.80% since the concentration of chips [2] - The margin trading data shows that as of August 18, the total margin balance is 93.54 million yuan, with a financing balance of 93.54 million yuan, reflecting an increase of 26.63 million yuan, or 39.80%, since the concentration of chips [2] Group 2 - In the first quarter, Dajia Weikang achieved operating revenue of 1.3 billion yuan, a year-on-year increase of 1.51%, while net profit was 3.14 million yuan, a year-on-year decrease of 83.82% [2] - The basic earnings per share is 0.0200 yuan, and the weighted average return on net assets is 0.18% [2]

Market Overview - The pharmaceutical commercial sector experienced a slight decline of 0.01% on August 13, with Huaren Health leading the drop [1] - The Shanghai Composite Index closed at 3683.46, up 0.48%, while the Shenzhen Component Index closed at 11551.36, up 1.76% [1] Stock Performance - Key stocks in the pharmaceutical commercial sector showed varied performance, with the following notable movements: - Seli Medical (603716) rose by 6.55% to a closing price of 31.09, with a trading volume of 556,200 shares and a transaction value of 1.671 billion [1] - Guofa Co. (600538) increased by 1.75% to 6.38, with a trading volume of 129,600 shares [1] - Huaren Health (301408) fell by 1.76% to 15.11, with a trading volume of 179,600 shares and a transaction value of 271 million [2] Capital Flow - The pharmaceutical commercial sector saw a net inflow of 33.73 million from institutional investors, while retail investors experienced a net outflow of 42.05 million [2] - Notable capital flows for specific stocks included: - Seli Medical had a net inflow of 10.9 million from institutional investors, while retail investors saw a net outflow of 2.46 million [3] - Yiyang Pharmaceutical (301015) had a net inflow of 6.29 million from institutional investors, but retail investors faced a net outflow of 31.02 million [3]

Core Viewpoint - Several shareholders across various companies are planning to reduce their stakes, with most reductions not exceeding 3% of total shares [1] Shareholder Reductions - Jiuliang Co., shareholders Rongxinliang and Zhuochu Guang plan to reduce their holdings by no more than 3% [1] - Inse Group, Orange Alliance Investment intends to reduce its stake by no more than 1% [1] - Xuelang Environment, shareholders Yang Jianping and Xu Huifen plan to reduce their holdings by a total of no more than 3% [1] - Haide Control, actual controller Guo Menglong plans to reduce his stake by no more than 3% [1] - Ailis, shareholders Shanghai Aixiang and Nantong Aiyun plan to reduce a total of no more than 13.5 million shares [1] - Huaxia Happiness, shareholders Ping An Life and Ping An Asset Management plan to reduce their holdings by a total of no more than 3% [1] - Tonglian Precision, actual controller Yang Hu plans to reduce his stake by no more than 2.375% [1] - Henggong Precision, shareholder Jingjinji Fund plans to reduce its stake by no more than 3% [1] - Dajia Weikang, director Zhong Xuesong plans to reduce his stake by no more than 1.7% [1] - Chuanwang Media, China Youth Publishing Group plans to reduce its stake by no more than 1% [1] Other Corporate Actions - Jinlihua Electric has terminated its plan for a major asset restructuring [1] - New Xiangwei has terminated the acquisition of 100% equity in Aixiangsheng [1]

Group 1 - The core viewpoint of the article highlights that Dajiahui Kang is focusing on the development of products and technologies in the field of regenerative medicine through collaborations with universities and hospitals [1] - The company aims to achieve scientific innovation and clinical transformation in regenerative medicine, thereby enhancing its production capabilities in this sector [1]

Group 1 - The article reports that 15 listed companies have disclosed share reduction plans, with no A-share increases on the same day [1] - Specific companies mentioned include Juguang Technology, Shiyun Circuit, Chuanwang Media, and others, indicating a trend of shareholder reductions [2] - The reductions range from 1% to over 3% of the companies' shares, with notable plans from major shareholders and executives [2]

Group 1 - The revenue composition of Dajia Weikang for the year 2024 is as follows: retail accounts for 51.44%, wholesale for 42.3%, industrial revenue for 5.73%, and services for 0.53% [1] Group 2 - Dajia Weikang announced that its board member, Mr. Zhong Xuesong, who holds approximately 19.29 million shares (9.39% of total shares), plans to reduce his holdings by up to 3.5 million shares (1.7% of total shares) through centralized bidding or block trading within three months starting from September 1, 2025 [3]

达嘉维康（301126）(301126.SZ)公告，公司董事钟雪松先生计划在2025年9月1日至2025年11月30日以集 中竞价或大宗交易的方式减持股份数量不超过350万股(占公司总股本的1.70%)。 ...

每经AI快讯，8月8日，达嘉维康公告，公司董事钟雪松计划自2025年9月1日至2025年11月30日期间， 通过集中竞价或大宗交易方式减持不超过350万股，占公司总股本的比例不超过1.70%。钟雪松当前持 有公司1928.84万股，占公司总股本的9.39%。此次减持的原因是出于个人资金需求，且钟雪松已严格履 行此前的股份锁定及减持承诺。 ...